This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Central nervous system tumors are the second most common malignancy of childhood and the leading cause of childhood cancer death despite multi-modality therapy with surgery, radiation therapy and chemotherapy. Effective new chemotherapy agents are required for the successful treatment for the successful treatment of these devastating tumors. CLORETAZINE , a novel alkylating agent that is a sulfonyl hydrazine prodrug, has demonstrated in vitro and in vivo anti-tumor activity against certain selected tumor cell lines that are resistant to currently approved bifunctional alkylating agents, including the chlorethylnitrosoureas (CENUs). This is a Phase I trial to estimate the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of CLORETAZINE (VNP40101M) administered intravenously daily for 5 consecutive days every six weeks to children with recurrent, progressive or refractory primary brain tumors. The MTD will be estimated in two strata: a) Stratum 1: Patients who received no prior XRT or focal XRT only and/or less than 2 prior myelosuppressive chemotherapy or biological therapy regimens and b) Stratum 2: Patients who received prior craniospinal XRT, high-dose chemotherapy, and/or more than 2 prior myelosuppressive chemotherapy or biological therapy regime
Showing the most recent 10 out of 459 publications